In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival

Differential expression of cytokeratins (CK) is a characteristic feature of chemoresistant luminal (KRT20) and chemosensitive intrinsic aggressive basal (KRT5) subtypes in muscle-invasive bladder cancer (MIBC). We investigated mRNA expression of KRT5 and KRT20 and its predictive value in stage pT1 b...

Full description

Saved in:
Bibliographic Details
Main Authors: Breyer, Johannes (Author) , Erben, Philipp (Author) , Kriegmair, Maximilian (Author)
Format: Article (Journal)
Language:English
Published: 10 January 2017
In: Virchows Archiv
Year: 2017, Volume: 470, Issue: 3, Pages: 267-274
ISSN:1432-2307
DOI:10.1007/s00428-017-2064-8
Online Access:Verlag, Volltext: http://dx.doi.org/10.1007/s00428-017-2064-8
Verlag, Volltext: https://link.springer.com/article/10.1007/s00428-017-2064-8
Get full text
Author Notes:Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Maximilian C. Kriegmair, Robert Stoehr, Markus Eckstein, Sebastian Eidt, Stefan Denzinger, Maximilian Burger, Arndt Hartmann, on behalf of the BRIDGE Consortium

MARC

LEADER 00000caa a2200000 c 4500
001 1577449940
003 DE-627
005 20220814190135.0
007 cr uuu---uuuuu
008 180710s2017 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00428-017-2064-8  |2 doi 
035 |a (DE-627)1577449940 
035 |a (DE-576)507449940 
035 |a (DE-599)BSZ507449940 
035 |a (OCoLC)1341013520 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Breyer, Johannes  |e VerfasserIn  |0 (DE-588)1155510593  |0 (DE-627)1017777454  |0 (DE-576)501694145  |4 aut 
245 1 0 |a In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival  |c Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Maximilian C. Kriegmair, Robert Stoehr, Markus Eckstein, Sebastian Eidt, Stefan Denzinger, Maximilian Burger, Arndt Hartmann, on behalf of the BRIDGE Consortium 
264 1 |c 10 January 2017 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 10.07.2018 
520 |a Differential expression of cytokeratins (CK) is a characteristic feature of chemoresistant luminal (KRT20) and chemosensitive intrinsic aggressive basal (KRT5) subtypes in muscle-invasive bladder cancer (MIBC). We investigated mRNA expression of KRT5 and KRT20 and its predictive value in stage pT1 bladder cancer. In retrospective analysis of clinical data and formalin-fixed paraffin-embedded tissues (FFPE) of patients with stage pT1 NMIBC who underwent transurethral resection of the bladder, a single-step RT-qPCR was used to measure mRNA expression. Furthermore, immunohistochemical (IHC) staining of CK20, panCK, and MIB1 was performed. Valid measurements were obtained from 231 samples out of a series of 284 patients. Spearman correlation revealed significant associations between mRNA and protein expression of KRT20/CK20 (ρ 0.6096, p < 0.0001) and MKI67/MIB1 (ρ 0.5467, p < 0.0001). A positive correlation was found between MKI67 and KRT20 expression (ρ 0.3492, p < 0.0001), while MKI67 and KRT5 were negatively correlated (ρ −0.1693, p = 0.01). High KRT20 expression (≥40.26) was significantly associated with worse recurrence free survival (RFS) (p = 0.001), progression-free survival (PFS) (p = 0.0003), and cancer specific survival (CSS) (p = 0.0414). The combination of high KRT20 expression and low KRT5 expression (<36.83) was associated with unfavorable RFS (p = 0.0038) and PFS (p = 0.0003) and proved to be the only independent predictor for RFS (p = 0.0055) and PFS (p = 0.0023) in multivariate analysis. KRT20 mRNA determination was superior to CK20 protein estimation with regard to RFS and PFS prediction. KRT20 and KRT5 mRNA quantification can predict recurrence and progression of stage pT1 NMIBC reflecting basal and luminal subtypes of MIBC and is superior to CK20 protein expression determined by IHC. 
700 1 |a Erben, Philipp  |d 1973-  |e VerfasserIn  |0 (DE-588)128501014  |0 (DE-627)373920997  |0 (DE-576)297181661  |4 aut 
700 1 |a Kriegmair, Maximilian  |d 1987-  |e VerfasserIn  |0 (DE-588)1049742745  |0 (DE-627)782573347  |0 (DE-576)403726840  |4 aut 
773 0 8 |i Enthalten in  |t Virchows Archiv  |d Berlin : Springer, 1847  |g 470(2017), 3, Seite 267-274  |h Online-Ressource  |w (DE-627)254910645  |w (DE-600)1463276-7  |w (DE-576)074754416  |x 1432-2307  |7 nnas  |a In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival 
773 1 8 |g volume:470  |g year:2017  |g number:3  |g pages:267-274  |g extent:8  |a In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival 
856 4 0 |u http://dx.doi.org/10.1007/s00428-017-2064-8  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://link.springer.com/article/10.1007/s00428-017-2064-8  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180710 
993 |a Article 
994 |a 2017 
998 |g 1049742745  |a Kriegmair, Maximilian  |m 1049742745:Kriegmair, Maximilian  |d 60000  |d 63100  |e 60000PK1049742745  |e 63100PK1049742745  |k 0/60000/  |k 1/60000/63100/  |p 5 
998 |g 128501014  |a Erben, Philipp  |m 128501014:Erben, Philipp  |d 60000  |d 63100  |e 60000PE128501014  |e 63100PE128501014  |k 0/60000/  |k 1/60000/63100/  |p 4 
999 |a KXP-PPN1577449940  |e 3017202518 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title":"In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival","title_sort":"In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival"}],"recId":"1577449940","origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"10 January 2017"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"recId":"254910645","origin":[{"dateIssuedDisp":"1847-","publisher":"Springer","dateIssuedKey":"1847","publisherPlace":"Berlin ; Heidelberg"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"Archiv für pathologische Anatomie und Physiologie und für klinische Medicin"},{"title":"Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin"},{"title":"Virchows Archiv / A"}],"note":["Gesehen am 06.12.05"],"corporate":[{"role":"isb","display":"European Society of Pathology"}],"id":{"issn":["1432-2307"],"zdb":["1463276-7"],"eki":["254910645"]},"disp":"In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survivalVirchows Archiv","physDesc":[{"extent":"Online-Ressource"}],"part":{"issue":"3","extent":"8","pages":"267-274","text":"470(2017), 3, Seite 267-274","year":"2017","volume":"470"},"language":["eng"],"title":[{"title_sort":"Virchows Archiv","title":"Virchows Archiv","subtitle":"official journal of the European Society of Pathology"}],"pubHistory":["1.1847 -"]}],"note":["Gesehen am 10.07.2018"],"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1007/s00428-017-2064-8"],"eki":["1577449940"]},"name":{"displayForm":["Johannes Breyer, Ralph M. Wirtz, Wolfgang Otto, Philipp Erben, Maximilian C. Kriegmair, Robert Stoehr, Markus Eckstein, Sebastian Eidt, Stefan Denzinger, Maximilian Burger, Arndt Hartmann, on behalf of the BRIDGE Consortium"]},"person":[{"family":"Breyer","given":"Johannes","role":"aut","display":"Breyer, Johannes"},{"family":"Erben","display":"Erben, Philipp","given":"Philipp","role":"aut"},{"given":"Maximilian","role":"aut","display":"Kriegmair, Maximilian","family":"Kriegmair"}]} 
SRT |a BREYERJOHAINSTAGEPT11020